GARS1: A Potential Drug Target for Various Diseases (G2617)

Target Name: GARS1

NCBI ID: G2617

GARS1

GARS1: A Potential Drug Target for Various Diseases

GARS1 (GARS-HUMAN) is a protein that is expressed in various tissues of the human body, including the lungs, heart, kidneys, and intestines. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

GARS1 is highly conserved across different species, and its sequence is highly conserved between humans and other animals. It is expressed in various tissues of the human body and is involved in various physiological processes, including cell signaling, inflammation, and fibrosis.

GARS1 has been identified as a potential drug target in the field of pharmacology. Its unique structure and various functions make it an attractive target for small molecules, including inhibitors, modulators, and agonists.

One of the key challenges in targeting GARS1 is its diverse expression pattern across different tissues and organisms. GARS1 is expressed in various tissues of the human body, including the lungs, heart, kidneys, and intestines, making it difficult to predict its response to small molecules.

GARS1 is also known to play a critical role in various physiological processes, including cell signaling, inflammation, and fibrosis. Its role in cell signaling is related to its involvement in intracellular signaling pathways, including the regulation of cell adhesion, migration, and survival.

GARS1 is involved in the regulation of cell adhesion and migration, which are critical processes for the development and maintenance of tissues and organs. It plays a role in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues and organs.

GARS1 is also involved in the regulation of cell proliferation and apoptosis. Its involvement in these processes makes it a potential target for small molecules that can promote cell growth and survival, or inhibit cell proliferation and apoptosis.

In addition to its role in cell signaling, GARS1 is also involved in the regulation of inflammation and fibrosis. Its involvement in these processes makes it a potential target for small molecules that can promote inflammation and fibrosis, or inhibit them.

GARS1 is a transmembrane protein that is involved in various physiological processes in the human body. Its unique structure and diverse expression pattern make it an attractive target for small molecules that can promote cell growth, survival, and inflammation.

GARS1 is a potential drug target that can be inhibited by small molecules to prevent the development and progression of various diseases, including cancer, cardiovascular disease, and fibrosis. Further research is needed to understand the full extent of GARS1's role in these diseases and to identify small molecules that can be effective treatments.

Protein Name: Glycyl-tRNA Synthetase 1

Functions: Catalyzes the ATP-dependent ligation of glycine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (Gly-AMP) (PubMed:17544401, PubMed:28675565, PubMed:24898252). Also produces diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs. Thereby, may play a special role in Ap4A homeostasis (PubMed:19710017)

The "GARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets